Articles

Videos

Podcasts

Clinical

Vaxneuvance was approved for an expanded indication by the FDA on June 22, 2022, for active immunization in children 6 weeks of age and older.

ACIP Unanimously Recommends Use of Pneumococcal 15-Valent Conjugate Vaccine for Infants and Children

Vaxneuvance is now indicated for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in individuals 6 weeks of age and older.

FDA Approves Expanded Indication for Vaxneuvance Pneumococcal Vaccine

New recommendations provide some harmonization to make it easier for clinicians to lower the barriers to assessing and identifying eligible patients for the pneumococcal vaccine.

2022 Updated CDC Recommendations for Pneumococcal Vaccination Lower Barriers to Assessing, Identifying Eligible Patients 

Expert emphasizes that it is important to acknowledge the critical role of pharmacists in overcoming barriers to vaccinations.

Expert: ‘Vaccination Is a Team Sport,’ Pharmacists Are Key Players

Ciprodex is approved for the treatment of ear infections, acute otitis media, and acute otitis externa.

Clinical Overview: Ciprofloxacin/Dexamethasone for Acute Otitis Media, Acute Otitis Externa

Voriconazole (Vfend) is an azole antifungal indicated for the treatment of invasive aspergillosis and Candidemia in non-neutropenics and other deep tissue Candida infections.

Daily Medication Pearl: Voriconazole (Vfend)

Any antibiotic use was associated with higher rates of IBD, and the risk went up substantially with each course.

Antibiotic Use, Inflammatory Bowel Disease Related in Older Adults 

Delafloxacin (Baxdela) is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia caused by designated susceptible bacteria.

Daily Medication Pearl: Delafloxacin (Baxdela)

Even before the COVID-19 pandemic, vaccine hesitancy has been a challenge among adult patient populations.

Adult Immunization Quality Landscape Presents Opportunities, Challenges

V116 is a novel 21-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease and pneumococcal pneumonia.

FDA Grants Breakthrough Designation to Merck's Investigational Pneumococcal Conjugate Vaccine Candidate

® Pneumococcal Resource Center is a comprehensive resource for clinical news and expert insights for any infection caused by the bacteria Streptococcus pneumoniae, or pneumococcus.